Vor Biopharma (NASDAQ:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 40,983 Shares

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold a total of 40,983 shares at an average price of $30.97, resulting in a transaction worth approximately $1.27 million.
• Following this sale, Reprogrammed Interchange LLC's ownership decreased to 1,333,792 shares, valued at over $41 million, indicating a 2.98% decrease in their stake.
• Vor Biopharma's share price recently fell to $30.22, a significant decline from its 12-month high of $65.80, amidst mixed analyst ratings and recent quarterly earnings underperforming expectations.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 40,983 shares of the company's stock in a transaction on Friday, October 10th. The shares were sold at an average price of $30.97, for a total value of $1,269,243.51. Following the completion of the transaction, the insider directly owned 1,333,792 shares in the company, valued at $41,307,538.24. This represents a 2.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, October 14th, Reprogrammed Interchange Llc sold 33,668 shares of Vor Biopharma stock. The shares were sold at an average price of $30.32, for a total transaction of $1,020,813.76.
• On Monday, October 13th, Reprogrammed Interchange Llc sold 22,006 shares of Vor Biopharma stock. The shares were sold at an average price of $32.44, for a total transaction of $713,874.64.
• On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The shares were sold at an average price of $32.07, for a total transaction of $1,567,709.88.
• On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The shares were sold at an average price of $33.87, for a total transaction of $2,549,123.94.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The shares were sold at an average price of $33.84, for a total transaction of $934,796.16.
• On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The shares were sold at an average price of $37.01, for a total transaction of $2,618,938.63.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The shares were sold at an average price of $37.83, for a total transaction of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The shares were sold at an average price of $39.83, for a total transaction of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The shares were sold at an average price of $39.19, for a total transaction of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12.

Vor Biopharma Price Performance

Shares of NASDAQ VOR traded down $0.59 during mid-day trading on Wednesday, reaching $30.22. The company had a trading volume of 724,134 shares, compared to its average volume of 393,854. Vor Biopharma Inc. has a twelve month low of $2.62 and a twelve month high of $65.80. The firm has a market capitalization of $207.01 million, a PE ratio of -0.11 and a beta of 2.07. The stock has a 50 day simple moving average of $37.28.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing analysts' consensus estimates of ($11.40) by ($32.20).

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds have recently modified their holdings of the business. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma in the second quarter worth $66,000. Goldman Sachs Group Inc. grew its position in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after purchasing an additional 58,247 shares during the last quarter. Jane Street Group LLC acquired a new stake in Vor Biopharma in the 1st quarter worth $140,000. OMERS ADMINISTRATION Corp bought a new position in shares of Vor Biopharma during the 1st quarter worth about $100,000. Finally, Money Concepts Capital Corp raised its position in shares of Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares during the last quarter. 97.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Stifel Nicolaus upgraded shares of Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 price objective for the company in a report on Wednesday, September 24th. Wall Street Zen cut shares of Vor Biopharma to a "strong sell" rating in a report on Saturday, June 28th. HC Wainwright reiterated a "buy" rating and issued a $60.00 price objective on shares of Vor Biopharma in a report on Thursday, August 14th. Robert W. Baird upgraded shares of Vor Biopharma from a "neutral" rating to an "outperform" rating and upped their price objective for the stock from $20.00 to $64.00 in a report on Wednesday. Finally, Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Vor Biopharma currently has a consensus rating of "Hold" and an average target price of $77.83.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.